文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

帕沙利布联合芦可替尼治疗骨髓纤维化应答欠佳患者的2期研究最终结果

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
PubMed 文献 · Blood Adv · 2024-01-01

这项2期研究评估了在稳定剂量芦可替尼基础上加用PI3Kδ抑制剂帕沙利布(parsaclisib)治疗原发性或继发性骨髓纤维化应答欠佳患者的给药方案、疗效和安全性。每日转每周给药组12周脾体积较基线下降≥10%的比例为28%,全每日给药组为59.5%;两组分别有14%和28%的患者MFSAF症状评分下降≥50%。加用帕沙利布可缩小脾大、改善症状,毒性可控。

要点

  • 每日转每周给药组12周脾体积下降≥10%者占28%,全每日给药组占59.5%。
  • 全每日给药组MFSAF和MPN-SAF症状评分下降≥50%者分别占28%和32%。
  • 新发3级和4级血小板减少在每日转每周给药组各占19%,全每日给药组分别占26%和7%。

核心结论

  • 在稳定剂量芦可替尼基础上加用帕沙利布可缩小脾大并改善症状,且毒性可控,适用于对芦可替尼应答欠佳的骨髓纤维化患者。

研究设计与样本

  • 2期研究,纳入原发性或继发性骨髓纤维化且对芦可替尼应答欠佳的患者,每日转每周给药组n=32,全每日给药组n=42。
  • 每日转每周给药组接受帕沙利布10或20 mg每日一次共8周、此后每周一次;全每日给药组接受帕沙利布5或20 mg每日一次共8周、此后5 mg每日一次。
  • 所有患者维持稳定剂量的芦可替尼。
  • 试验注册号NCT02718300。

主要发现

  • 12周时脾体积较基线下降≥10%的患者比例:每日转每周给药组28%,全每日给药组59.5%。
  • 12周时MFSAF症状评分下降≥50%的患者比例:每日转每周给药组14%,全每日给药组28%。
  • 12周时MPN-SAF症状评分下降≥50%的患者比例:每日转每周给药组18%,全每日给药组32%。
  • 最常见的非血液学治疗中出现的不良事件为恶心(23%)、腹泻(22%)、腹痛和乏力(各19%)、咳嗽和呼吸困难(各18%)。
  • 新发3级血小板减少在每日转每周给药组占19%,全每日给药组占26%;新发4级血小板减少在每日转每周给药组占19%,全每日给药组占7%,均通过剂量中断处理;血红蛋白水平保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yacoub A, Borate U, Rampal RK, et al. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024. PMID: 38290135. doi:10.1182/bloodadvances.2023011620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。